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Introduction:  Prostate cancer is one of the commonest, malignancies affecting elderly males. Prostatic basal
cell carcinoma, (PBCC) accounts for less than 0.01% of all prostate cancers.
Observation:  A 32-year-old man presented with hematuria and lower urinary tract symptoms. Clinical
examination showed hard, nodular enlarged prostate with multiple penile hard nodules. His prostate-specific
antigen (PSA) level was 0.91 ng/mL. Histopathological examination of the fingerguided prostate biopsy
revealed a malignancy with features of basal cell carcinoma. Further imaging studies were performed and
metastases were found in both lungs, penis, pelvic lymph nodes and right ischium.
Conclusion:  The current case highlights PBCC as a diagnostic pitfall which presented in a young adult with
a normal PSA level.
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rostate cancer is the second commonest malignancies affecting
ales worldwide [1]. It is usually considered as the disease of
lderly but approximately 10% of the 241,740 men diagnosed with
rostate cancer in 2012 represent early-onset prostate cancer defined
erein as men diagnosed at 55 years of age or younger [2,3]. Ade-
ocarcinoma is the most common histological subtype of prostatic
arcinoma which arises from secretory cells of the glands [1]. The
nd hosting by Elsevier B.V. This is an open access article under the CC
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Figure  1  Panel of microphotographs of the prostatic core biopsy. (A) Histopathology of the prostatic core biopsies showing left core completely




























































0x); (C) The tumor cells show nuclear pleomorphism and perineural i
ositive and Ki-67 index is around 80–85% (immunoperoxidase, 10×)
esions arising from the basal cells of the gland are less common
nd can range from basal cell hyperplasia to a rare entity called as
rostatic basal cell carcinoma (PBCC). PBCC cases comprise less
han 0.01% of malignant prostate tumors [4–6]. Frankel and Craig
7] were the first one to describe this entity in the year 1974. This
umor has been variously named in the literature (adenoid cystic
arcinoma, adenoid cystic-like tumor, basaloid tumor) but the cur-
ent World Health Organization terminology is basal cell carcinoma
8]. Clinically, the patient usually presents with lower urinary tract
ymptoms and/or hematuria but can also presents with bladder out-
et obstruction and metastasis [9]. Histopathology establishes the
iagnosis but requires a careful distinction from its benign mimick-
rs. The clinical behavior of PBCC remains unclear due to its rarity.
ence, no standard therapeutic approaches are currently established.
e present a case of 32-year-old man with PBCC with an insight into
he histopathological and immunohistochemical (IHC) profile. The
etails of the clinical behavior and follow-up has been provided. The
iagnosis of PBCC has many pitfalls, and hence, precise distinction
rom other mimickers is crucial for precise treatment.
ase  report
 32-year-old man presented to the Urology clinic with hematuria
nd lower urinary tract symptoms. Clinical examination revealed
nlarged, hard, nodular prostate fixed to lateral pelvic walls and
ultiple hard nodules in the shaft of penis. The serum prostate-
pecific antigen (PSA) level was within normal limits (0.91 ng/mL).
ltrasound showed enlarged prostate (100 cc) with heterogeneous
exture along with few ill-defined lesions measuring 5–9 mm. All
ther routine investigations were normal. The patient underwent





ation (H and E, 40×); (D, E, F) The tumor cells are p63 positive, bcl2
icroscopic examination of the biopsy specimen revealed a tumor
rranged in nests, cords and cribriform pattern (Fig. 1A and 1B). Few
oci of necrosis were also noted. The tumor cells show a moderate
egree of anisonucleosis and pleomorphism. Perineural invasion
as identified (Fig. 1C). A panel of immunohistochemistry markers
as performed to identify the lesion as benign versus malignant and
o confirm the basal cell phenotype. The tumor cells were strongly
ositive for p63 (nuclear) and bcl-2 (cytoplasmic) (Fig. 1D and 1E)
nd there was patchy positivity for 34βE12, thereby confirming their
asal phenotype. These tumor cells were negative for CK20, PSA,
D117, and AMACR and hence ruling out acinar adenocarcinoma
nd other metastatic malignancies. Ki-67 proliferation rate was as
igh as 80–85% (Fig. 1F) indicative of malignant behavior. Thus, a
iagnosis of PBCC was entertained.
-weighted magnetic resonance imaging (MRI) revealed enlarged
rostate with ill-marginated outline, extra-capsular extension, and
nfiltration into the base of bilateral seminal vesicles, the base of uri-
ary bladder, anterior wall of rectum, anal canal and penis (Fig. 2,
 & B). Gallium68 Prostate Specific Membrane Antigen (PSMA)
ET-CT scan was also performed to look for the metastases. It
evealed parenchymal and pleural nodules in bilateral lung fields,
argest measuring 2 ×  1.5 cm. Also, there were bilateral pelvic lym-
hadenopathy, solitary right ischium lesion and bilateral corpora
avernosum lesions on this PET-CT scan (Fig. 2, C, D & E).
ubsequently, the patient was started on Docetaxel chemotherapy
ith androgen deprivation therapy (injection leuprolide). Patient
eceived four cycles of chemotherapy. However, in view of worsen-
ng clinical symptoms of penile pain with development of bilateral
ydroureteronephrosis and deranged renal function, chemotherapy
as stopped. Patient underwent bilateral percutaneous nephrostomy
lacement and received palliative radiation therapy to shaft of penis
n view of persistent pain associated with metastatic priapism refrac-
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Figure  2  Panel of imaging studies highlighting the primary and metastatic lesions. T1 and T2 wted magnetic resonance images showing (A)
altered signal intensity in the whole prostate with a poorly marginated hypointense focal lesion in left lobe and infiltration into bilateral seminal
vesicles (left > right) and base of urinary bladder. Also, loss of fat plane with anterior wall of rectum is noted. (B) Hypointense ill-defined lesion
involving bilateral corpora cavernosa with larger measuring 3.7 ×  1.7 cm on right side. Gallium68 Prostate Specific Membrane Antigen (PSMA)
























cavernosa, larger on the right. (E) PSMA avid parenchymal and pleural
tory to analgesics. Further chemotherapy has been planned to be
resumed once the palliative radiation therapy is completed.
Discussion
PBCC is a rare subtype of prostate carcinoma. Less than 100 cases
have been reported since its description in 1974. The mean age at
presentation is 50 years, ranging from 28 to 78 years [10]. PBCC is
usually located in the transition zone [11].
Though PBCC is considered as a prostate carcinoma, PSA levels are
usually normal, unlike adenocarcinoma because of its cell of origin
being from basal layer [12]. This is one of the reasons that this entity
has a low clinical suspicion of malignancy. Furthermore, in contrast
to adenocarcinoma, the Gleason score is not used to grade the tumor
due to the basal cell origin. The challenge for a histopathologist to
diagnose this lesion is to differentiate it from benign mimickers
like basal cell hyperplasia as well as sometimes from adenocarci-
noma with a cribriform pattern. PBCC shows an infiltrative pattern,
extra-prostatic extension, perineural invasion, necrosis, and stromal
desmoplasia, unlike its benign mimickers. To identify the basal ori-
gin, immunostains like 34βE12 and p63 are helpful; to distinguish it
from basal cell hyperplasia, bcl-2 and Ki-67 helps (high expression
in PBCC) and to rule out adenocarcinoma, PSA immunohistochem-
istry is used. Also, metastatic urothelial carcinoma also needs to
be ruled out with the help of CK20 [13]. Most of these differen-






ns in bilateral lung fields.
BCC outcome is currently considered to be uncertain and depends
pon the stage of the disease. Some tumors behave in a locally
ggressive fashion, with the involvement of the bladder and peripro-
tatic tissue and some others show metastatic disease to multiple
rgans [12]. Ali et al. [11], have suggested that basaloid pattern
ith large solid nests and necrosis is a feature of aggressive disease
ith adverse outcome.
ur case showed metastases to lungs, penis, pelvic lymph nodes
long with bony metastasis indicative of poor outcome. Point of
nterest is that metastases often involve the liver, lung, and bowel
ut rarely reported in bone, as is commonly observed in prostate
denocarcinoma [14]. There are no consensus guidelines for the
reatment of this malignancy owing to its rare occurrence. Various
herapeutic modalities reported in the literature are radical prosta-
ectomy, chemotherapy, androgen deprivation therapy, radiotherapy
r combination of these [12]. The poor prognostic indicators are
xtra-prostatic extension/distant metastases [12]. A recent study
nvestigated the molecular mechanism of this malignancy and
howed it as an aggressive tumor with a frequent loss of phosphatase
nd tensin homolog (PTEN) expression and an over-expression of
pidermal growth factor receptor (EGFR) [15].
onclusionistopathology in conjunction with IHC is the gold standard for the
efinite diagnosis of prostatic basal cell carcinoma. Clinical suspi-
ion of malignancy with a normal PSA level should alert a urologist

































rostatic malignancies. Tumor necrosis, histologically pure PBCC,
igh Ki-67, and presence of metastasis remain important poor prog-
ostic factors. However, the definitive therapy for this malignancy
emains yet to be established.
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